Tag: enzyme-responsive
Degrader–Antibody Conjugates (DACs): Advances, Promise, and Emerging Safety Paradigms
Traditional antibody-drug conjugates (ADCs) have delivered cytotoxic payloads—often tubulin or topoisomerase inhibitors—directly to antigen-positive tumor cells, providing targeted cell killing while limiting off-target effects. However, the emergence of degrader–antibody conjugates (DACs), particularly those based on proteolysis-targeting chimeras (PROTACs) and molecular glues, has introduced a new therapeutic strategy: harnessing targeted protein degradation rather than inhibition.
